Ameresco Celebrates the Completion Solar Canopy Project with the City of Pendleton, Oregon
FRAMINGHAM, Mass. & PENDLETON, Ore.--(BUSINESS WIRE)-- Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition and the City of Pendleton in Oregon today hosted a ribbon-cutting ceremony to celebrate the completion of a 240-kilowatt (kW) solar photovoltaic (PV) canopy system at the Pendleton Wastewater Treatment and Resource Recovery Facility (WWTRRF).
This innovative solar canopy--the first of its kind in the region--represents a major milestone in the City's ongoing efforts to enhance energy resilience, efficiency and innovation, supported by Ameresco. The solar canopy is expected to annually generate 325,000 kilowatt-hours (kWh) of electricity, which will offset approximately 30% of the WWTRRF's total energy consumption.
'This project marks a major step forward in our commitment to developing efficient and resilient solutions for our city,' said Kyle Willman, Superintendent, at Wastewater Treatment Resource Recovery Facility. 'The solar canopy not only helps reduce our energy costs and environmental footprint, but it also enhances the performance of our wastewater treatment facility in ways that benefit the entire community. We're grateful for our partnership with Ameresco and for the state and local support that made this forward-thinking investment possible.'
In addition to providing on-site energy production and cost savings, the canopy shades the WWTRRF's chlorine contact chamber, helping to improve water quality, reduce effluent temperature and support a healthier aquatic ecosystem. The project is part of a multiphase infrastructure improvement initiative and was delivered through an Energy Savings Performance Contract (ESPC) with Ameresco, who provided price and performance guarantees and helped ensure participation from disadvantaged and local businesses.
The Pendleton WWTRRF project was funded through a combination of state grants (including ODOE's C-REP grant), utility incentives and city resources. As part of the City's ongoing efforts to increase the resilience and reliability of the WWTRRF, plans are underway for a future battery energy storage system (BESS) to complement the solar canopy and further decrease the operational costs of the facility.
'We are proud to partner with the City of Pendleton in its mission to build a resilient future,' said Lou Maltezos, President of Central & Western USA, Canada Regions at Ameresco. 'This solar canopy project is a great example of how innovative energy solutions can deliver meaningful economic benefits and support essential city infrastructure. We're not only improving operational efficiency but also contributing to the health of the local ecosystem and empowering the community with long-term energy savings.'
For more information about Ameresco and its energy efficiency and resiliency infrastructure solutions, visit www.ameresco.com.
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE: AMRC) is a leading energy solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering diversified generation solutions to Federal, state and local governments, utilities, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.
About the City of Pendleton
The City of Pendleton is a vibrant and active community with a rich heritage and a lively history. Located at the base of the Blue Mountains in Eastern Oregon, Pendleton is well known for its world-class Pendleton Round-Up rodeo, a thriving arts culture and many historic attractions. To learn more, visit www.pendletonor.gov.
The announcement of completion of a customer's project contract is not necessarily indicative of the timing or amount of revenue from such contract, of Ameresco's overall revenue for any particular period or of trends in Ameresco's overall total project backlog. This project was included in Ameresco's previously reported contracted backlog as of March 31, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
37 minutes ago
- Associated Press
Metavesco Launches Bitcoin Treasury Strategy, Secures $750,000 Financing
CUMMING, GA - July 1, 2025 ( NEWMEDIAWIRE ) - Metavesco, Inc. (OTC: MVCO), a publicly traded holding company operating Epic Labor and other growth assets, today announced it has launched Phase 1 of its Bitcoin Treasury Strategy after closing a $750,000 five-year term loan. Proceeds will be deployed immediately to: 'This financing is a lifeline that does more than bridge working capital; it lets us flip the switch from forced sellers to long-term holders,' said Ryan Schadel, President & CEO. 'Our three-phase treasury plan begins with hodling our self-mined coins, then ramps to systematic market purchases funded by capital inflows from our staffing business, expected to begin later this year, and finally allocating 10-15% of our total assets into Bitcoin.' Bitcoin Treasury Roadmap Loan Highlights About Metavesco, Inc. Metavesco is a diversified holding company focused on acquiring and managing assets across multiple sectors, including consumer packaged goods and staffing services. The company is dedicated to long-term growth through organic expansion, strategic acquisitions and innovative market solutions. Safe Harbor Statement This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words 'may', 'would', 'will', 'expect', 'estimate', 'can', 'believe', 'potential', and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on Contact: Ryan Schadel 6783415898 [email protected] View the original release on
Associated Press
37 minutes ago
- Associated Press
Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ('Envoy Medical'), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: 'These latest patent issuances continue to expand the depth and breadth of our intellectual property and reflect our commitment to advancing hearing technology that is integrated into patients' lives,' said Brent Lucas, CEO of Envoy Medical. 'Our team remains focused on delivering differentiated solutions that move the industry forward and are designed to meet the real-world needs of people living with hearing loss.' Envoy Medical's fully implanted technologies are designed to eliminate external components and leverage the natural anatomy of the ear for sound detection, offering a fundamentally different experience from traditional hearing aids or partially implanted systems. For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit To be added to the Envoy Medical email distribution list, please email [email protected] with COCH in the subject line. About Envoy Medical, Inc. Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life. About the Fully Implanted Acclaim® Cochlear Implant We believe the fully implanted Acclaim Cochlear Implant ('Acclaim CI') is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI) The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing. *Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use. Important safety information for the Esteem FI-AMEI can be found at: Additional Information and Where to Find It Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'will,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'target' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward Looking Statements' in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical. ### Investor Contact: Phil Carlson KCSA Strategic Communications O: 212.896.1233 E: [email protected] SOURCE: Envoy Medical, Inc. To view the source version of this press release, please visit
Associated Press
38 minutes ago
- Associated Press
One World Products, Inc. Appoints William Rowland as Chief Financial Officer
LAS VEGAS, NV - July 1, 2025 ( NEWMEDIAWIRE ) - One World Products, Inc. ('OWP') (OTCQB: OWPC), a leading developer of sustainable materials for automotive and industrial markets, is pleased to announce the appointment of William 'Bill' Rowland, CPA, as its new Chief Financial Officer. Rowland brings decades of leadership in financial management, operations, and corporate development across a diverse range of industries. He has held senior executive positions at both private and public organizations and brings a proven track record of driving operational excellence, managing complex financial initiatives, and delivering strategic growth. A graduate of Indiana University and a former consultant at KPMG, Rowland has led financial restructuring and expansion strategies across various sectors. His leadership experience includes roles as CFO, CDO, and Corporate Secretary, as well as involvement in development management firms, both as founder and executive. Most recently, he has directed acquisition and development strategies for healthcare and resort assets nationwide. 'We are excited to welcome Bill to the One World team,' said Isiah Thomas, Chairman and CEO of One World Products. 'His extensive financial leadership and operational background will be a tremendous asset as we continue scaling our automotive initiatives and expanding our presence in sustainable materials. Bill's experience and insight will help us strengthen our financial operations and strategically position the company for long-term growth.' Rowland will be instrumental in leading the Company's financial planning and analysis, reporting, and operational strategy as OWP moves forward with commercialization and new market expansion. About One World Products, Inc. One World Products is a producer of sustainable materials serving the automotive, packaging, and consumer goods sectors. The Company partners with industry leaders to develop high-performance solutions that reduce environmental impact and support the transition to renewable inputs in global supply chains. For more information, please visit Contact: One World Products, Inc. 800-605-3210 View the original release on
